Vienna-based nyra health, a provider of an AI-based platform for neurological therapy, announces the completion of a €20 million Series A financing round to further expand its technology platform in the DACH region, accelerate its expansion in the US, and pursue its goal of establishing a new standard for data-driven neurorehabilitation.
The round is led by Armira Growth. Existing investors such as Wellington Partners, Crane Venture Partners, which now oversees MassMutual Ventures’ investments, and EVER Pharma are participating again. This follows a €4.5 million Seed raise back in 2023, as covered by EU-Startups.
Moritz Schöllauf, CEO and co-founder, nyra health, says: “From the outset, our goal was to make our services widely available to those affected. Everyone who needs therapy after a stroke or other neurological disease should have access to effective, individualised care – regardless of where they live or how well their own healthcare system is set up. With this round of financing, we are taking another step in this direction.”
In the broader 2025–2026 funding landscape, several European health- and neurology-related ventures have also secured capital, illustrating sustained investor interest in neurological disease innovation and digital care tools.
Notably, Aerska in Dublin raised around €17 million Seed to advance RNA interference-based medicines targeting diseases of the central nervous system, aimed at addressing hard-to-treat brain disorders. EG 427, a Paris-based BioTech, completed a €27 million Series B to propel genetic medicine programmes focused on chronic neurological conditions.
Early-stage companies such as Strolll, with a reported €12.2 million raise for augmented reality applications in neurorehabilitation, and Neu Health (~€1.9 million) targeting AI-enabled care for Parkinson’s and dementia, further reflect activity at the intersection of tech and neurological care.
Meanwhile, Hemi Health in Denmark secured €4 million Seed financing to scale digital therapeutic and clinical services for migraine, concussion and headache disorders.
Within this context, nyra health’s €20 million Series A for its AI-based neurorehabilitation platform aligns with a broader trend of funding into neurological and HealthTech innovation across Europe.
Collectively these rounds add up to over €60 million in funding, pointing to a diverse but converging focus on neurological disease biology, digital therapeutics and AI-driven care solutions, with investors backing both drug-centric BioTech and software-enabled clinical tools in the sector.
Christian Figge, Managing Partner, Armira Growth, adds: “Neurological rehabilitation can be made significantly more effective through digital solutions, especially in the area of speech ability. nyra health is considered a true category creator with a proprietary AI-based solution that seamlessly connects the entire care chain – from inpatient therapy to outpatient aftercare to home use – for the first time.”
Founded in 2021 by an interdisciplinary team of experts in the fields of neurology, machine learning, and regulatory affairs, nyra health is developing an AI platform for neurological rehabilitation.
It is currently used in over 100 rehabilitation clinics, in the digital rehabilitation aftercare programme of the German Pension Insurance Fund, and by patients with the support of over 28 health insurance companies.
According to the company, neurological diseases such as stroke, dementia, and traumatic brain injury cause €65 billion in costs annually in Germany alone – mainly because care often stops or significantly decreases in intensity after discharge from the hospital. This results in gaps in care for those affected and rising costs due to inadequate follow-up care and avoidable long-term consequences for health insurance companies and cost bearers.
myReha has reportedly been shown to significantly increase therapy time while delivering substantial cost savings: 28 statutory and private health insurance companies already automatically reimburse myReha. More than 40 million insured individuals now have access to structured, AI-based home therapy with real-time feedback.
“We were also particularly impressed by the strong clinical evidence and deep integration into the German standard of care, which already gives nyra health access to over 40 million insured individuals. On this basis, the company is ideally positioned to define the market for digital neurorehabilitation internationally as well,” shares Christian.
At its heart is the MDR Class IIa certified medical device myReha. Patients train speech, cognition, fine motor skills, and everyday abilities with AI-supported real-time feedback. Specially developed speech models analyse pathological speech at the level of pronunciation, word retrieval, syntax, and semantic structure. At the same time, reaction times, error profiles, and training dynamics are continuously evaluated.
Based on this data, the therapy automatically adapts to performance level, fatigue, and progress. In a randomized controlled study, the additional use of myReha showed significantly greater improvements in cognitive and language functions compared to standard therapy.
At the same time, nyra insights structures the control by specialists: therapists see language developments, therapy intensity, and progress curves in real time, adjust programs, and create documentation automatically. This is complemented by the AI-supported Content Studio, which dynamically generates personalised therapy content specifically for therapy practices based on individual performance data.
After today’s announcement, additional clinic groups in the DACH region will be connected and existing reimbursement models in Germany, Austria, and Switzerland will be expanded in a targeted manner. At the same time, the company is preparing to enter the US market.
nyra health is also investing in the technological advancement of its platform. The focus is on expanding multimodal AI models for therapeutic interaction and diagnostics. These are being developed as part of a funded research project worth €4.2 million and scientifically validated in collaboration with leading US research universities.
Read the orginal article: https://www.eu-startups.com/2026/02/with-e65-billion-lost-each-year-to-stroke-and-dementia-in-germany-nyra-health-secures-e20-million-to-scale-digital-neurotherapy/
